Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-22-017878
Filing Date
2022-05-04
Accepted
2022-05-04 16:34:09
Documents
76
Period of Report
2022-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q rgnx-10q_20220331.htm   iXBRL 10-Q 2331647
2 EX-10.1 rgnx-ex101_95.htm EX-10.1 61970
3 EX-31.1 rgnx-ex311_94.htm EX-31.1 16935
4 EX-31.2 rgnx-ex312_93.htm EX-31.2 16906
5 EX-32.1 rgnx-ex321_92.htm EX-32.1 11292
  Complete submission text file 0001564590-22-017878.txt   10043798

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA rgnx-20220331.xsd EX-101.SCH 67250
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE rgnx-20220331_cal.xml EX-101.CAL 61960
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE rgnx-20220331_def.xml EX-101.DEF 212113
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE rgnx-20220331_lab.xml EX-101.LAB 475851
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rgnx-20220331_pre.xml EX-101.PRE 366408
70 EXTRACTED XBRL INSTANCE DOCUMENT rgnx-10q_20220331_htm.xml XML 2282379
Mailing Address 9804 MEDICAL CENTER DRIVE ROCKVILLE MD 20850
Business Address 9804 MEDICAL CENTER DRIVE ROCKVILLE MD 20850 240-552-8181
REGENXBIO Inc. (Filer) CIK: 0001590877 (see all company filings)

EIN.: 471851754 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37553 | Film No.: 22892068
SIC: 2836 Biological Products, (No Diagnostic Substances)